EU life sciences leadership needs radical new model, warns Belgian researcher

EURACTIV - Belgian and European biotech competitiveness will fail unless there's a redesign of how high-risk therapies move from labs to patients, warns a KU Leuven researcher involved in translating high-risk science into early-stage trials. The warning comes as Brussels advances the Biotech Act and a sweeping reform of EU pharmaceutical rules. Read more

[[Photo by Solskin - Getty Images]]